HT
SPRY icon

Headlands Technologies’s ARS Pharmaceuticals SPRY Stock Holding History

Headlands Technologies’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$387K Buy
+48,206
New +$462K 0.04% 431

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Headlands Technologies's SPRY Position: Q1 2026 in Review

Headlands Technologies opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 48,206 shares worth $387K. The stake represents 0.04% of the portfolio and ranks #431 among its holdings.

202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Headlands Technologies held 48,206 shares of ARS Pharmaceuticals worth $387K as of Q1 2026.
  • ARS Pharmaceuticals was a new Headlands Technologies position in Q1 2026.
  • ARS Pharmaceuticals made up 0.04% of Headlands Technologies's portfolio in Q1 2026, its #431 holding.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.